Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The era of high-dose, long-term prednisone for generalized myasthenia gravis (gMG) is giving way to smarter, targeted approaches. At a recent clinical forum, neurologists discussed how FcRn inhibitors, complement C5 inhibitors, and emerging CAR-T therapies are reshaping treatment sequencing. The key message: aggressive steroid use carries real risks, and newer agents offer faster, safer alternatives.
At an October 2026 forum in North Carolina, Duke Health neurologist Karissa L. Gable, MD, led a panel discussion on the evolving treatment landscape for generalized myasthenia gravis (gMG). A central theme was reducing reliance on high-dose corticosteroids — Gable noted she caps outpatient prednisone at 20 mg/day to avoid inadvertently triggering a myasthenic crisis, a preventable but costly event. Diagnostic delays also remain a serious issue, with some patients — particularly racial and ethnic minorities — waiting nearly 19 months for a diagnosis.
Targeted therapies are increasingly filling the gap. FcRn inhibitors like efgartigimod, rozanolixizumab, and nipocalimab can reduce IgG levels within a week, making them ideal bridges while slower agents like azathioprine or mycophenolate (which take 6–9 months) kick in. For more severe or bulbar disease, complement C5 inhibitors such as eculizumab and ravulizumab appear to offer an edge based on clinical experience.
Key Takeaways:
Why it matters: As targeted therapies multiply, clinicians have a real opportunity to move gMG patients off long-term steroids — reducing side effects and improving quality of life — but thoughtful sequencing and early escalation are key.